How venture works
The funding staircase
Pre-seed through IPO is a sequence of checks that each buy down a different risk — not one round with a louder letter.
Startup financing is a staircase, not a single check. Each step — pre-seed, seed, Series A, B, C+, growth, pre-IPO — buys a different kind of progress: product truth, go-to-market repeatability, scale, or public-market readiness. Investors at each step underwrite different risks and expect different proof.
Round letters are marketing labels, not laws. A "seed" in 2021 sometimes looked like a 2015 Series A. AI companies in 2024–2026 sometimes jumped stages on usage and narrative alone. Always ask what risk the round is priced to remove.
The big idea
| Stage | Job of the money | Typical proof investors want |
|---|---|---|
| Pre-seed | Incorporate, build v1, find first users | Team, insight, early product |
| Seed | Reach product-market fit signals | Retention, design partners, early revenue |
| Series A | Make growth repeatable | Scalable acquisition, often meaningful ARR |
| Series B | Scale what works | Efficient growth, team depth |
| Series C+ | Expand markets / products | Category leadership path |
| Growth / pre-IPO | Optimize, M&A, prepare markets | Predictable financials, controls |
Stage and instrument travel together. Pre-seed and seed are mostly SAFEs or convertible notes; priced seeds exist but are heavier. Series A and later are usually priced preferred with a full term sheet. Bridges sit between formal stages — see down rounds and bridges.
Raising a "Series A" on a SAFE without a lead who will own the board seat is often a labeling exercise. A large priced seed with heavy control terms can feel like an A. Read the rights, not the press release.
Walking through a skip
Skipping a stage is possible (seed → B) when metrics and narrative jump. It concentrates dilution negotiation into fewer, larger rounds and raises execution risk if the jump was hype. Adding extra seed extensions avoids a premature A but stacks SAFE ownership that SAFE math will reveal at conversion — sometimes painfully.
Common mistakes
- Pitching Series A metrics with a pre-seed company. The staircase is about which risk is gone, not which letter you want.
- Trusting the press-release label. Rights and board seats tell you the stage.
- Mixing a SAFE "A" with no lead. Someone has to own the round.
Check yourself
A company has a prototype and a waitlist, and is raising a "Series A." What risk has not been bought down yet?
Product-market fit and repeatable growth. That is still pre-seed or seed work, whatever the letter says.
Why might a priced seed feel like Series A?
Heavy control terms and a real board seat can look like A, even if the label says seed. Read the rights.
Key takeaways
- Each stage buys down a different risk: team/product → fit → repeatability → scale → public readiness.
- Letters are labels. Ask which uncertainty the check is priced to remove.
- Instruments follow the staircase: SAFEs early, priced preferred from A onward.
- Skipping a stage concentrates dilution; extra seed SAFEs stack conversion pain.
Further learning
Next, what the checks actually cost: round sizes and dilution.